InVision Precision Cardiac Amyloid vs RTHawk
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A specializes in the AI-powered detection of cardiac amyloidosis using echocardiography, aiming for earlier diagnosis of this specific condition. In contrast, Tool B focuses on streamlining and accelerating cardiac MRI acquisition and analysis, offering general cardiac function measurements and workflow efficiencies. While both contribute to cardiovascular diagnostics, they operate on distinct imaging modalities and address different primary challenges within the diagnostic process.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
InVision Precision Cardiac Amyloid is an AI-powered software that utilizes echocardiography to specifically detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection. In contrast, RTHawk is an AI-driven software that simplifies and accelerates cardiac MRI acquisition and analysis, offering features like one-click automation and real-time imaging for broader cardiac diagnostic efficiency.
InVision Precision Cardiac Amyloid is deployed as Software as a Medical Device (SaMD) and is designed to integrate into clinical workflows for echocardiography labs, evaluating transthoracic echocardiogram studies. RTHawk is an on-premise solution that integrates with existing MRI scanners to assist with and automate the cardiac MRI acquisition process.
InVision Precision Cardiac Amyloid offers AI-powered detection of both AL and ATTR Cardiac Amyloidosis from echocardiogram studies, including precise assessment of wall thickness. RTHawk provides AI-assisted MRI acquisition, automates standard cardiac views, includes artifact detection, optimizes inversion time, offers 4D flow measurement, and provides preliminary measures of left ventricular function such as ejection fraction, volumes, and mass.
InVision Precision Cardiac Amyloid's AI algorithm is evidence-based, with its peer-reviewed research published in JAMA Cardiology, supporting its design for earlier detection and reduction of misdiagnosis in cardiac amyloidosis. It has also received FDA Breakthrough Device Designation.
For a practice primarily focused on echocardiography and the early detection of cardiac amyloidosis, InVision Precision Cardiac Amyloid would be more suitable due to its direct integration with echo workflows and specific diagnostic focus. Conversely, a practice with a strong cardiac MRI program looking to enhance acquisition efficiency and advanced analysis would find RTHawk more beneficial for streamlining MRI exams.